




Are We on the Same Page? A Cross-Sectional Study of Patient–Clinician Goal Concordance in Rheumatoid Arthritis

Jennifer L. Barton,¹  Sheila Markwardt,² Meike Niederhausen,¹ Allison Schue,³ Jacob Dougherty,³ Patricia Katz,⁴  Somnath Saha,¹ and Edward H. Yelin⁴ 

Objective. Patient–clinician goal concordance is associated with improved outcomes in certain chronic diseases but not explored in rheumatoid arthritis (RA). We examined goal concordance, correlates of concordance, and the association of concordance with health outcomes.

Methods. Adult patients with RA seen at least 1 time in the prior 12 months at 1 of 2 rheumatology clinics participated. Patients and their clinicians independently ranked top 3 goals for RA treatment from 8 options before a routine visit. Patients completed postvisit surveys on health, demographic information, health literacy, and adherence. Goal concordance was defined as the patient’s number 1 goal being among the clinician’s top 3 goals for that patient. Bivariable and multivariable logistic regression models were used to examine correlates of concordance.

Results. Patients were 58% female and 16% Spanish-speaking, and 29% had limited health literacy. Among 204 patient–clinician dyads, 20% were goal-discordant. “Have less pain” was selected by both patient and clinician in 81% of dyads, followed by “have fewer problems doing daily activities” by 63%. Otherwise, clinicians prioritized avoiding side effects, whereas patients ranked improved sleep, fatigue, and mood. Longer disease duration was associated with discordance (median 13.3 years, interquartile range [IQR] 5.2–20 among discordant vs. 7 years, IQR 4–14; $P = 0.039$); higher depressive symptoms were associated with concordance (8.1% vs. 24%; $P = 0.04$). Goal concordance was associated with higher medication adherence (adjusted odds ratio 2.76 [95% confidence interval 1.01, 7.56]).

Conclusion. One in 5 patient–clinician dyads had discordant treatment goals. Goal concordance was associated with higher medication adherence. Studies to improve goal elicitation and communication of patients with RA’s priorities are needed.

INTRODUCTION

Current treatment paradigms for rheumatoid arthritis (RA), a chronic disabling condition with high societal and personal cost, include shared decision-making (SDM) between patients and clinicians (1). A key element of effective SDM is understanding patients’ goals, which often reflect desired improvements in quality of life, and how they align with or differ from clinicians’ goals. For clinicians who care for patients with RA, goals are commonly driven by clinical metrics and guidelines, including the treat-to-target approach, with a target of low disease activity or remission. Patients’ goals are often different. In a systematic literature review of patients with RA goals, we identified more than 400 goals that fell into 4 distinct areas: 1) the bodily experience of RA; 2) achieving normalcy and

maintaining wellness; 3) social connectedness and support; and 4) interpersonal and health care system interactions (2). Patients with RA report challenges in sharing their treatment goals with their clinicians (3). Despite achievement of remission, patients continue to report lower quality of life compared with the general population, suggesting that even patients who reach the clinical goal of remission do not necessarily reach their own individual goals and continue to experience limitations, including fatigue and mood disturbances such as depression and anxiety (4).

Does it matter if clinicians and patients share common goals? Agreement around shared goals or “goal concordance” is associated with improved outcomes in other complex chronic conditions, such as diabetes mellitus (5), and during end of life care (6). Effective patient with RA–clinician communication is central

This content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the Department of Veterans Affairs.

Dr. Barton’s work was supported by the NIH (grant K-23-AR-064372).

¹Jennifer L. Barton, MD, MCR, Meike Niederhausen, PhD, Somnath Saha, MD, MPH: Center to Improve Veteran Involvement in Care, Veterans Affairs Portland Health Care System, Oregon and Oregon Health & Science University, Portland; ²Sheila Markwardt, MPH: Oregon Health & Science University, Portland; ³Allison Schue, DO, Jacob Dougherty, BA: Center to Improve Veteran Involvement in Care, Veterans Affairs Portland Health Care System, Portland,

Oregon; ⁴Patricia Katz, PhD, Edward H. Yelin, PhD: University of California, San Francisco.

Author disclosures are available at <https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1002%2Facr.24794&file=acr24794-sup-0001-Disclosureform.pdf>.

Address correspondence via email to Jennifer L. Barton, MD, MCR, at bartoje@ohsu.edu.

Submitted for publication April 13, 2021; accepted in revised form September 23, 2021.

SIGNIFICANCE & INNOVATIONS

- Goal concordance (or agreement) between patients and clinicians can lead to improved health outcomes in chronic disease but has not been examined in rheumatoid arthritis (RA).
- One in 5 patient–clinician dyads were discordant around RA treatment goals.
- Patients with longer RA disease duration were more likely to be discordant with their clinician. This may highlight shifting goals over time for patients (more focus on function and mood with longer duration).
- Goal concordance was independently associated with higher adherence, which suggests that clearer communication around treatment goals may lead to improved adherence and outcomes.

to accurate diagnosis, symptom assessment, treatment selection, and avoidance of unsafe use of costly therapies, yet communication around goals in RA is largely understudied. Patient preferences and values vary significantly (7), and thus alignment of goals is essential in RA and may serve as a model for other chronic conditions with complex decision-making around medications, safety, and cost. Patient–clinician discordance around the assessment of disease activity has been consistently reported in RA (8–10) and underscores communication gaps between patients and clinicians. Patients with RA have expressed reluctance or fear of raising issues around pain with their clinicians (4). These barriers to alignment between clinicians and patients impede effective SDM and delivery of patient-centered care, in which clinicians and patients work together toward the same set of goals, determined by patient preferences and priorities.

Additional barriers to effective communication and SDM in RA in majority English-language–dominant health care settings include limited health literacy (LHL), limited English language proficiency (LEP), and depressed mood (8). In a prior study of more than 500 patients with RA, we found suboptimal decision-making communication among those with LHL and LEP (11). These known barriers to communication have yet to be studied with regard to goal concordance. Therefore, in this study, we aimed to 1) measure goal concordance between patients with RA and their clinicians; 2) examine whether barriers to communication (LEP, LHL, or depression) were independently associated with goal discordance; and 3) evaluate the association of goal concordance with outcomes of self-efficacy, trust in the physician, medication adherence, and disease activity.

PATIENTS AND METHODS

Study design. We conducted a cross-sectional study to measure goal concordance (or agreement) between patients with RA and their rheumatology clinicians and sought to 1) identify correlates of goal concordance and 2) measure the association of goal concordance with patient outcomes.

Patient participants. Eligible patients were consecutively enrolled from 2 rheumatology clinical sites (university-based and Veterans Affairs [VA] outpatient-based rheumatology specialty clinics) beginning in October 2016. Patient participants included in this study must have been seen by a rheumatology clinician at least once over the previous 12 months, were at least 18 years of age, and met the 2010 American College of Rheumatology criteria for RA. Clinician participants included rheumatology attendings, fellows in training, or advance practice partners (nurse practitioner or physician's assistant). The research protocol was approved by the joint Portland VA/Oregon Health & Science University (OHSU) Institutional Review Board (IRB 15851); patient participants provided written informed consent, and clinician participants consented via information sheet.

Procedures. Patient participants with upcoming clinic appointments were screened for study eligibility, and those meeting inclusion criteria were mailed a letter to introduce the study, which included a return letter in which patients could opt out or request more information. Among those who did not opt out, patients were contacted before their appointment or approached in the clinic waiting room, and if interested, consented to enroll in the study. Enrolled patients completed a brief goals measure (Supplementary Methods 1, which is available on the *Arthritis Care & Research* website at <http://onlinelibrary.wiley.com/doi/10.1002/acr.24794>) before the clinic visit. The measure was developed by the study team based on a review of the literature on patient goals (2), focus groups (12), and multistakeholder input. Patient goals identified in the systematic review and focus groups were grouped into broad domains in the goals measure in order to create a brief, operable tool for clinical use. The goals measure asks patients to rank the top 3 most important things they want their RA treatment to do. Options were have less pain, improve function, work outside the home, avoid side effects, improve sleep, feel less tired, improve mood, not affect fertility, or “other,” in which patients can write in a goal. Clinician participants were asked independently of the patient goals measure to rank their top 3 priorities for treatment for their patient from the same list of goals patients used before the clinic visit for each unique patient (Supplementary Methods 2, which is available on the *Arthritis Care & Research* website at <http://onlinelibrary.wiley.com/doi/10.1002/acr.24794>). After completion of the goals measure, patients would then proceed to their usual clinic visit as scheduled, and after the visit patients completed a second survey, which included items on demographic characteristics, health literacy, disease duration, medications, depressive symptoms, posttraumatic stress disorder (PTSD), self-efficacy, trust in the physician, disease activity, and medication adherence. Patient participants were compensated with a \$25 gift card.

Goal concordance. The measure of interest in all analyses was patient–clinician goal concordance. This was defined as the patient's number 1 goal being ranked among the top 3 listed by

the clinician. This definition is guided by prior literature on goal concordance in diabetes mellitus (5,13).

Primary correlates of concordance: LEP, LHL, depressive symptoms. Using methodology established by Karliner et al to ascertain LEP (14), participants responded to 2 questions to evaluate English language proficiency. Health literacy was measured using a single-item literacy screener, a self-reported and validated measure that has been used among populations with RA in other studies (15,16). Depressive symptoms were measured using the Patient Health Questionnaire-8 (PHQ-8), an 8-item self-report measure, validated in multiple languages and used among patients with LHL (17). Scores range from 0 to 24 with a score of at least 10 corresponding to moderate depressive symptoms or greater.

Patient outcomes. In our study model, we hypothesized that goal concordance would be associated with downstream outcomes of increased self-efficacy, higher trust in the physician, improved medication adherence, and lower disease activity.

Self-efficacy. Self-efficacy was measured using the English-language validated 6-item “Self-efficacy for Managing Chronic Disease” scale (18). Item scores range from 1 to 10 with higher scores reflecting greater self-efficacy; the summary score is the mean of the 6 items. For Spanish speakers, we used the “Spanish Arthritis Self-Efficacy” 8-item scale (19); item score range and scoring are the same as the English language scale.

Trust in the physician. Low trust in the physician has been shown to be associated with suboptimal communication around shared decision-making (11) as well as confidence in deciding to take a disease-modifying antirheumatic drug (DMARD) (20). We measured trust with the 11-item Trust in Physician scale (21) that has been validated in patients with RA (22). Responses are summed, and the value is transformed to a 0–100 scale. A score below the median was considered suboptimal. After data collection had been completed, it was noted that the final 3 questions of the scale were inadvertently omitted from the survey. Despite this, the Cronbach’s alpha for the scale with 8 items was 0.799, and it felt reasonable to proceed with including it as an a priori selected patient outcome.

Adherence. We measured self-report adherence with the validated 8-item Morisky’s Medication Adherence Scale (MMAS-8) (23). The MMAS-8 scoring system classifies patients as having low, moderate, or high adherence; in prior studies, patients who had low or moderate adherence were considered nonadherent (24). We dichotomized adherence at low/moderate compared with high.

Disease activity. We captured disease activity using a composite measure, the Clinical Disease Activity Index (CDAI), which is a sum of 4 components: 28 tender joint count, 28 swollen joint count, patient global assessment of disease activity, and clinician global assessment of disease activity. CDAI scores range from 0 to 76. A minimal clinically important difference in CDAI is 6 (25).

Covariates. Patient demographic characteristics of age, sex (male vs. female), race and ethnicity (White, Black, Latinx/Hispanic, vs. other), partner status (coupled, which included married or living with a partner, yes vs. no), education (high school or less vs. some college or more) and annual income (<\$40,000 vs. ≥\$40,000) were all captured by self-report on the survey. Given that we included a number of Veteran patient participants in the study and PTSD has been associated with incident RA (26) and poorer prognosis/more aggressive disease activity (27), participants completed a 4-item screener for PTSD (28), and if they scored 3 or higher on the screener, they were instructed to complete a full measure of PTSD (29).

Analysis. Descriptive statistics were used to summarize patient characteristics according to goal concordance. Goals ranked by patient and clinician were described graphically and were enumerated as those selected by both patient and clinician, by patient only, and by clinician only.

We performed a series of bivariate analyses to test for differences in patient characteristics, primary correlates, and patient outcomes according to goal concordance, for which we used chi-square tests for categorical variables and *t*-tests or Mann-Whitney U tests for continuous variables. To determine the association of our primary correlates with concordance, and of concordance with patient outcomes, we built a series of regression models, including both unadjusted (no covariates) and adjusted models. We used the following analysis approaches: logistic regression for all primary correlates of concordance, trust in the physician, and medication adherence; and linear regression for self-efficacy and disease activity. Our first step in creating an adjusted model was to retain covariates in the model if they changed the regression coefficient, for either our primary correlates of concordance or concordance itself, by ~20% or more (e.g., a change-in-estimate variable selection strategy) (30). Next, we used a forward selection procedure, based on Bayesian information criteria, to incorporate covariates that improved model fit. Last, we considered site and sex in our adjusted models, because these would adjust for differences among patients at the clinic and system level. When building our primary correlates of concordance models, we were conservative in the number of covariates we added to each model in order to minimize the number of subjects per variable and, for this reason, did not include site and sex in the same model; these factors in combination greatly impacted the standard error because of the predominance of male

patients at the VA site. Models presented include site because this factor provided a better model fit. Additionally, we used Firth's bias penalized likelihood logistic regressions to reduce potential bias generated from the small sample size in certain covariate profiles. Because multiple patients were treated by a single clinician, we assessed if clustering by clinician should be taken into account; preliminary models incorporating clustering by clinician did not improve model fit, and for this reason, we do not present these models. Model assumptions were checked, and no violations were noted. All analyses were performed in Stata/SE, version 15, and graphics were created in R version 4.0.2 using package ggplot2 version 3.3.3.

RESULTS

A total of 208 patient-clinician dyads were enrolled (estimated patient participation rate 62%); goal-ranking instructions were not followed by 1 patient and 2 clinicians, and 1 patient

lacked clinical information, leaving 204 dyads included in the analysis, 63% from the university and 37% from the VA (Table 1). Overall, patients were predominantly female (58%) with an average age of 57.2 years (SD 14.2) and median 8 years disease duration (interquartile range [IQR] 4–16). Nearly one-third had a high school education or less (31.6%), 15.1% had LEP, and 29% had LHL. There were a total of 15 clinicians (8 female), which included 14 physicians (4 of whom were rheumatology fellows) and 1 advanced practice partner.

Goal concordance. A total of 164 dyads (80%) met the definition of concordance (patient's top goal ranked among the clinician's top 3). This agreement was largely driven by 124 dyads being concordant on “have less pain” as a goal (132 patients selected it as their number 1 goal) (Figure 1). The next most frequently selected goal was “have fewer problems doing daily activities,” with 32 dyads concordant on this goal (61.8% selected by both patient and clinician) (Table 2).

Table 1. Patient characteristics, overall and by concordance*

Characteristics	Total (n = 204)	Discordant (n = 40)	Concordant (n = 164)	P
Site				
OHSU	122 (62.7)	26 (65.0)	96 (62.2)	0.86
VA	76 (37.3)	14 (35.0)	62 (37.8)	
Sex				
Male	85 (41.7)	18 (45.0)	67 (40.9)	0.72
Female	119 (58.3)	22 (55.0)	97 (59.1)	
Age, mean \pm SD years	57.2 \pm 14.2	58.2 \pm 15.1	56.9 \pm 14.0	0.62
Language				
English	168 (84.4)	35 (92.1)	133 (82.6)	0.21
Spanish	31 (15.6)	3 (7.9)	28 (17.4)	
Limited English language proficiency	30 (15.1)	3 (7.9)	27 (16.8)	0.17
Coupled	110 (57.9)	22 (61.1)	88 (57.1)	0.71
Education				
High school or less	60 (31.6)	15 (40.5)	45 (29.4)	0.24
Some college or more	130 (68.4)	22 (59.5)	108 (70.6)	
Income				
<\$40,000	85 (45.5)	12 (33.3)	73 (48.3)	0.14
>\$40,000	102 (54.5)	24 (66.7)	78 (51.7)	
People in household, median (IQR)	2 (2–4)	2 (2–3)	2 (2–4)	0.92
Race and ethnicity				
White	123 (68.3)	25 (78.1)	98 (66.2)	0.62
Black	6 (3.3)	0 (0.0)	6 (4.1)	
Latinx/Hispanic	39 (21.7)	6 (18.8)	33 (22.3)	
Other	12 (6.7)	1 (3.1)	11 (7.4)	
Limited health literacy	55 (28.6)	13 (35.1)	42 (27.1)	0.42
Disease duration, median (IQR) years	8 (4–16)	13 (5–21)	7 (4–15)	0.039
Number of medications, median (IQR)	1 (1–2)	1 (0–2)	1 (1–2)	0.10
Depressive symptoms	38 (20.8)	3 (8.1)	35 (24.0)	0.040
PTSD	13 (7.1)	2 (5.6)	11 (7.5)	1.00
Self-efficacy score, mean \pm SD	6.3 \pm 2.1	6.3 \pm 2.1	6.3 \pm 2.1	0.96
Trust in the physician	106 (53.8)	19 (51.4)	87 (53.0)	0.74
Disease activity score (CDAI), mean \pm SD	12.8 \pm 10.5	10.5 \pm 9.7	13.2 \pm 10.8	0.21
Medication adherence				
High	63 (33.5)	7 (20.6)	56 (36.4)	0.11
Low/medium	125 (66.5)	27 (79.4)	98 (63.6)	

* Values are the number (percentage). CDAI = Clinical Disease Activity Index; IQR = interquartile range; OHSU = Oregon Health & Science University; PTSD = posttraumatic stress disorder; VA = Veterans Affairs.




Figure 1. This plot displays the clinician-selected top goals for RA treatment (y-axis) and the patient-ranked goals (x-axis) as either first, second, or third for each goal listed on the goals measure. Wording on the measure asked patients and clinicians to select the top 3 most important things for treatment to do for them from a list of 8 options. We display results from the most commonly selected goals here: 1) have less pain; 2) have fewer problems doing my daily activities (function); 3) be able to work outside the home; and 4) avoid side effects from medicine. A green dot indicates that the clinician selected the patient's number 1 goal (defined as "goal concordant"); a purple dot indicates the goal was selected by either or both patient or clinician but did not meet the definition of concordance. The size of the dot reflects the number of times it was selected. RA = rheumatoid arthritis.

"Improve sleep" was ranked by 20.1% of patients, with 0 dyads concordant on this goal. Similarly, "feel less tired" was selected by 27.5% of patients but only 6.4% of clinicians. "Improve mood" was a goal selected by 12.3% of patients but only 1 clinician. Interestingly, goal ranking by patients varied by disease duration. Patients with early RA (less than 2 years duration) were more likely to select "work outside the home" and "improve mood" than those with longer disease duration, who more often chose "have fewer problems with daily activities" (Supplementary Table 1, available on the *Arthritis Care & Research* website at [http://onlinelibrary.wiley.com/doi/10.1002/](http://onlinelibrary.wiley.com/doi/10.1002/acr.24794)

[acr.24794](http://onlinelibrary.wiley.com/doi/10.1002/acr.24794)). "Other" goals included ambulation, preventing joint damage or deformities, going back to work, gaining knowledge about prognosis, and living normally.

Correlates of goal concordance. In bivariate analyses, disease duration was shorter in goal concordant (median 7 years, IQR 4–15) compared with discordant (median 13 years, IQR 5–21) dyads ($P = 0.04$). Depressive symptoms by PHQ-8 (score at least 10) were more common among patients in concordant dyads (24.0% vs. 8.1%; $P = 0.04$). Multivariable logistic models constructed for each primary predictor of interest are shown in

Table 2. Patient and clinician selection of RA treatment goals organized according to goals selected by both patient and clinician, selected by the patient only, and selected by the clinician only*

Goal (selected as 1 of top 3 goals)	Selected by both	Selected by patient only	Selected by clinician only
Have less pain	166 (81.4)	14 (6.9)	21 (10.3)
Have fewer problems doing daily activities	126 (61.8)	7 (3.4)	65 (31.9)
Be able to work outside the home	21 (10.3)	35 (17.2)	42 (20.6)
Avoid side effects from medicine	53 (26.0)	29 (14.2)	75 (36.8)
Improve sleep	3 (1.5)	38 (18.6)	6 (2.9)
Feel less tired	13 (6.4)	56 (27.5)	13 (6.4)
Improve mood	1 (0.5)	25 (12.3)	1 (0.5)
Not affect ability to have children	1 (0.5)	8 (3.9)	0 (-)
Other	0 (-)	11 (5.4)	4 (2.0)

* Values are the number (percentage). RA = rheumatoid arthritis.

Table 3. Results of unadjusted and adjusted logistic regression models comparing the odds of RA patient–clinician goal concordance for three primary predictors of interest*

Main predictor	Unadjusted OR (95% CI)	P	Adjusted OR (95% CI)†	P
Model 1				
Limited health literacy	0.680 (0.320–1.442)	0.314	0.569 (0.260–1.247)	0.159
Disease duration, years			0.958 (0.925–0.993)	0.019
Income (>\$40,000)			0.610 (0.282–1.318)	0.208
VA site			1.333 (0.602–2.952)	0.478
Model 2				
LEP	2.074 (0.642–6.696)	0.223	1.507 (0.452–5.025)	0.505
Disease duration, years			0.966 (0.934–1.000)	0.051
Income (>\$40,000)			0.598 (0.278–1.282)	0.186
Model 3				
Depressive symptoms	3.138 (0.981–10.037)	0.054	2.802 (0.848–9.251)	0.091
Disease duration, years			0.965 (0.931–1.000)	0.051
Income (>\$40,000)			0.618 (0.278–1.375)	0.238
VA site			1.378 (0.618–3.070)	0.433

* 95% CI = 95% confidence interval; LEP = Limited English language proficiency; OR = odds ratio; RA = rheumatoid arthritis.

† For each model, the adjusted analyses included variables listed for each model, respectively.

Table 3. LHL was associated with a nonsignificant lower odds of goal concordance (adjusted odds ratio [AOR] 0.57 [95% CI 0.26, 1.25]), whereas depressive symptoms were associated with

a nonsignificant higher odds of goal concordance (AOR 2.8 [95% CI 0.85, 9.25]). LEP, when adjusted for disease duration and income, was not associated with goal concordance. In all 3

Table 4. Results of unadjusted and adjusted logistic and linear regression models assessing the association between patient outcomes and patient–clinician goal concordance as the main effect*

Outcome	Unadjusted estimate, OR (95% CI)	P	Adjusted estimate, OR (95% CI)	P
Self-efficacy score				
Goal concordant	−0.019 (−0.822, 0.785)	0.963	0.532 (−0.294, 1.357)	0.205
Female sex	NA	NA	−0.372 (−1.271, 0.526)	0.414
Income >\$40,000	NA	NA	0.412 (−0.324, 1.148)	0.271
Some college or more	NA	NA	−0.305 (−1.103, 0.493)	0.451
Coupled	NA	NA	−0.002 (−0.724, 0.720)	0.996
Depressive symptoms	NA	NA	−2.027 (−2.814, 1.240)	0.000
Disease duration, years	NA	NA	−0.009 (−0.042, 0.023)	0.566
VA site	NA	NA	−0.269 (−1.165, 0.628)	0.554
Trust in the physician				
Goal concordant	1.129 (0.552, 2.310)	0.740	1.361 (0.610, 3.038)	0.452
Female sex	NA	NA	0.899 (0.379, 2.130)	0.809
Income >\$40,000	NA	NA	2.430 (1.281, 4.610)	0.007
Depressive symptoms	NA	NA	0.695 (0.317, 1.522)	0.362
Disease duration, years	NA	NA	1.010 (0.977, 1.045)	0.546
VA site	NA	NA	1.055 (0.434, 2.563)	0.906
Disease activity score*				
Goal concordant	2.698 (−1.566, 6.962)	0.213	1.609 (−2.838, 6.056)	0.476
Female sex	NA	NA	5.021 (0.119, 9.923)	0.045
Income >\$40,000	NA	NA	−0.412 (−3.928, 3.104)	0.817
Some college or more	NA	NA	−1.053 (−4.938, 2.832)	0.593
Health literacy	NA	NA	0.075 (−3.760, 3.910)	0.969
Depressive symptoms	NA	NA	7.129 (2.992, 11.266)	0.001
Disease duration, years	NA	NA	0.044 (−0.127, 0.215)	0.612
VA site	NA	NA	0.847 (−4.313, 6.007)	0.746
High medication adherence				
Goal concordant	2.204 (0.902, 5.388)	0.083	2.760 (1.007, 7.564)	0.048
Female sex	NA	NA	0.989 (0.386, 2.532)	0.981
Income >\$40,000	NA	NA	0.863 (0.421, 1.766)	0.686
Some college or more	NA	NA	2.799 (1.192, 6.575)	0.018
Depressive symptoms	NA	NA	0.528 (0.219, 1.272)	0.155
Disease duration, years	NA	NA	1.016 (0.981, 1.052)	0.372
VA site	NA	NA	0.968 (0.372, 2.517)	0.947

* 95% CI = 95% confidence interval; NA = not assessed; OR = odds ratio; VA = Veterans Affairs. Disease activity measured by the Clinical Disease Activity Index.

models, longer disease duration was associated with lower odds of goal concordance (AOR 0.96 [95% CI 0.93, 0.99] in the health literacy model).

Goal concordance as predictor of health outcomes.

Using separate models for each outcome, in both unadjusted and adjusted analyses, we did not see an association of goal concordance with self-efficacy, trust in the physician, or disease activity (Table 4). Goal concordance was associated with higher medication adherence (AOR 2.76 [95% CI 1.01, 7.56]) when controlling for sex, income, education, depression, disease duration, and site. Education (more than high school) was also associated with high medication adherence (AOR 2.80 [95% CI 1.19, 6.58]).

Sensitivity analysis: examination of goal concordance excluding the ranking of “less pain.”

As described above, the majority of patient-clinician dyads (80%) were goal concordant, which was driven by the prioritization by both patients and clinicians of “have less pain.” RA patients are asked about pain levels at every visit, and pain is included in many disease activity measures for RA. Given the diverse and broad range of patient goals, we explored the proportion of concordant dyads when pain reduction was not included in the list of goals. If a patient ranked pain reduction as their number 1 goal, we then considered their number 2 goal as their first choice for this analysis. It should be noted that 126 patients (62%) ranked pain reduction as their number 1 goal, and of these 126, 119 (94%) were concordant. In contrast, 116 of dyads (57%) were concordant when pain reduction was not considered as part of the goal measure. With respect to predictors of goal concordance, depressive symptoms were no longer associated with concordance, and the direction of the association shifted (AOR 0.77 [95% CI 0.37, 1.62]). This suggests that the finding of the association of depressive symptoms and goal concordance in the main analysis was overwhelmingly driven by agreement around the goal of having less pain among patients with more depressive symptoms. In addition, LHL was associated with lower odds of goal concordance when adjusting for disease duration, income,

and site (AOR 0.50 [95% CI 0.26, 0.95]) in this sensitivity analysis. Goal concordance was no longer associated with medication adherence when pain reduction was excluded from the goals list (AOR 1.11 [95% CI 0.56, 2.18]).

Additional sensitivity analyses in which the definitions of goal concordance were altered to be stricter revealed a lower frequency of concordance (Table 5): 1) patient's number 1 ranked goal among the clinician's first and second ranked goals: 59% concordant; 2) patient's number 1 ranked goal among the clinician's number 1 goal: 41% concordant.

DISCUSSION

In this novel, cross-sectional study of more than 200 patients with RA and their rheumatology clinicians, 1 in 5 dyads lacked agreement around the most important goals. The current treatment paradigm of treat-to-target prioritizes the clinician-driven goal of low disease activity or remission, whereas patient goals are typically more complex and often go unelicited or unaddressed (2,12,31). Goal concordance was driven overwhelmingly by the prioritization of having less pain. The majority of patients (64%) selected pain reduction as their number 1 goal, and, of these, 94% were goal concordant. Beyond pain reduction, RA patients more often ranked goals of improved sleep, less fatigue, and improved mood, whereas clinicians chose avoiding side effects of medicine. Clinicians may prioritize the avoidance of side effects in part because of a sense of responsibility for causing them through prescribing practices.

Depressive symptoms were associated with nearly 3 times the odds of being goal concordant, although this relationship did not reach statistical significance. Patients with RA have concomitant depression in up to 40% of cases; depression is a known barrier to communication and has been identified as a predictor of patient-clinician discordance around the assessment of disease activity in RA (8). Despite higher rates of goal concordance among those with depression in this study, the focus on pain may not allow space for discussion of goals around mood (selected by 12.3% of patients, 0.5% clinicians). LHL and LEP were not significantly associated with goal concordance in the main analysis; however, the sensitivity analysis without the ranking of pain reduction showed lower odds of concordance among those with LHL (AOR 0.50 [95% CI 0.26, 0.95]). Our prior work identified LHL as a significant predictor for suboptimal communication around shared decision-making (11). Our goals measure prioritized the use of plain language to describe goals and included input from patients in its development. Communication of goals and the high priority for less pain, because it is discussed at every RA clinical visit, may not be impacted by literacy or LEP status. Given that LEP and LHL are known predictors of suboptimal communication (32), future studies of interventions to enhance goal concordance in RA and other chronic diseases should continue to measure and include patients with these

Table 5. Results of sensitivity analysis: frequency of patient-clinician goal concordance across 3 definitions of concordance and without pain ranked as a goal

Concordance definition	Concordance, no. (%)
Number one ranked goal of patient among first, second, and third ranked goals of clinician	164 (80)
Number one ranked goal of patient among first and second ranked goals of clinician	121 (59)
Number one ranked goal of patient among number one ranked goal of clinician	83 (41)
Number one ranked goal of patient among first, second, and third ranked goals of clinician (without pain)	116 (57)

barriers to communication in the development and testing of goal elicitation tools and strategies. Furthermore, the adoption of universal precautions for health literacy improves medication adherence in RA (33).

Goal concordance was associated with higher medication adherence. This finding reinforces the importance of communication and shared goals in selection of therapy and has potential impacts on longer-term control of disease activity (34); however, longitudinal studies are needed. Medication adherence to DMARDs in RA has been reported to be as low as 25% (35). A recent study in which patients were asked to rank the most important factors related to DMARD adherence identified improving symptoms, maintaining independence, and shared decision-making as high priorities (36). In addition, we have identified beliefs in the necessity of medications to be associated with improved treatment adherence in RA (37).

Although this study adds to our understanding of goal concordance in RA, it is not without limitations. The cross-sectional study design does not allow for determination of causality. We used a cross-sectional measure of adherence as a proxy to examine the relationship between goal concordance and adherence; ideally, one would look at impact of goal concordance on adherence over time. Participants were located in a single geographic location, which may limit generalizability. However, the inclusion of patients and clinicians from 2 separate health care systems, 1 with a large number of male patients with RA, is a strength, because this is an often understudied population because of the natural higher prevalence of RA among women. The proportion of patients with LEP was low and may not allow for identification of independent associations of LEP with goal concordance. Our inclusion of LHL and LEP patients in this study is a strength, given these are known predictors of poor communication and poorer outcomes in RA. Three items from the 11-item Trust in Physician scale were inadvertently omitted from the survey; however, the Cronbach's alpha for the 8-item scale was 0.799, and thus this was included as an a priori selected patient outcome. Despite an extensive systematic literature review and series of focus groups that informed the goals measure, the major themes of "bodily experience, achieving normalcy and wellness, social connectedness and support, and interpersonal interactions" may not be comprehensively represented in the tool. However, all participants had the option to select "other" on the measure and write in a goal of their choosing. We did not collect data on patient-clinician relationship duration, which may influence goal concordance; however, all patients had been seen at least once in the prior 12 months as part of eligibility criteria. Our definition of goal concordance was generous and may have underestimated the degree of discordance in our population; the sensitivity analysis, which removed the number 1 goal of having less pain, revealed more than a doubling of the rate of discordance (20% vs. 43%) when this rather expected goal is removed. Additionally, if we alter the definition of concordance to agreement

of the patient's number 1 ranked goal among number 1 or first and second goals listed by the clinician, the frequency of goal discordance increases as well (59% and 41%, respectively). Future studies may require refining the definition of goal concordance in RA and measuring this concept in multiple different settings and populations. We sought to measure concordance around goals for therapy; however, equally important may be agreement around strategies to achieve those goals. A shared treatment approach is integral to shared decision-making. Establishing shared goals can be considered the first step in the SDM journey.

In this novel study of more than 200 patients with RA and their rheumatology clinicians, 1 in 5 dyads lacked agreement around the most important goals. Goal concordance was independently associated with higher medication adherence. Systematic approaches to communication around goals and shared decision-making may create an environment in which sharing goals is normalized and working together to achieve them through both pharmacologic and nonpharmacologic means becomes standard of care. Areas of sleep, fatigue, and mood need more explicit elicitation on the part of clinicians, and broader consideration of nonpharmacologic therapy (e.g., more discussion of physical activity) and enhanced collaborative care with mental health and primary care clinicians should be studied.

AUTHOR CONTRIBUTIONS

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be submitted for publication. Dr. Barton had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study conception and design. Barton, Markwardt, Niederhausen, Katz, Saha, Yelin.

Acquisition of data. Schue, Dougherty.

Analysis and interpretation of data. Barton, Markwardt, Niederhausen, Katz, Saha, Yelin.

REFERENCES

- Smolen JS. Treat-to-target as an approach in inflammatory arthritis. *Curr Opin Rheumatol* 2016;28:297–302.
- Hulen E, Ervin A, Schue A, et al. Patient goals in rheumatoid arthritis care: a systematic review and qualitative synthesis. *Musculoskeletal Care* 2017;15:295–303.
- Strand V, Wright GC, Bergman MJ, et al. Patient expectations and perceptions of goal-setting strategies for disease management in rheumatoid arthritis. *J Rheumatol* 2015;42:2046–54.
- Scott IC, Machin A, Mallen CD, et al. The extra-articular impacts of rheumatoid arthritis: moving towards holistic care. *BMC Rheumatol* 2018;2:32.
- Heisler M, Vijan S, Anderson RM, et al. When do patients and their physicians agree on diabetes treatment goals and strategies, and what difference does it make? *J Gen Intern Med* 2003;18:893–902.
- Paladino J, Bernacki R, Neville BA, et al. Evaluating an intervention to improve communication between oncology clinicians and patients with life-limiting cancer: a cluster randomized clinical trial of the serious illness care program. *JAMA Oncol* 2019;5:801–9.

7. Fraenkel L, Nowell WB, Michel G, et al. Preference phenotypes to facilitate shared decision-making in rheumatoid arthritis. *Ann Rheum Dis* 2018;77:678–83.
8. Barton JL, Imboden J, Graf J, et al. Patient-physician discordance in assessments of global disease severity in rheumatoid arthritis. *Arthritis Care Res (Hoboken)* 2010;62:857–64.
9. Desthieux C, Hermet A, Granger B, et al. Patient-physician discordance in global assessment in rheumatoid arthritis: a systematic literature review with meta-analysis. *Arthritis Care Res (Hoboken)* 2016;68:1767–73.
10. Khan NA, Spencer HJ, Abda E, et al. Determinants of discordance in patients' and physicians' rating of rheumatoid arthritis disease activity. *Arthritis Care Res (Hoboken)* 2012;64:206–14.
11. Barton JL, Trupin L, Tonner C, et al. English language proficiency, health literacy, and trust in physician are associated with shared decision making in rheumatoid arthritis. *J Rheumatol* 2014;41:1290–7.
12. Barton JL, Hulen E, Schue A, et al. Experience and context shape patient and clinician goals for treatment of rheumatoid arthritis: a qualitative study. *Arthritis Care Res (Hoboken)* 2018;70:1614–20.
13. Zulman DM, Kerr EA, Hofer TP, et al. Patient-provider concordance in the prioritization of health conditions among hypertensive diabetes patients. *J Gen Intern Med* 2010;25:408–14.
14. Karliner LS, Naples-Springer AM, Schillinger D, et al. Identification of limited English proficient patients in clinical care. *J Gen Intern Med* 2008;23:1555–60.
15. Barton JL, Koenig CJ, Evans-Young G, et al. The design of a low literacy decision aid about rheumatoid arthritis medications developed in three languages for use during the clinical encounter. *BMC Med Inform Decis Mak* 2014;14:104.
16. Morris NS, MacLean CD, Chew LD, et al. The single item literacy screener: evaluation of a brief instrument to identify limited reading ability. *BMC Fam Pract* 2006;7:21.
17. Kroenke K, Strine TW, Spitzer RL, et al. The PHQ-8 as a measure of current depression in the general population. *J Affect Disord* 2009;114:163–73.
18. Lorig KR, Sobel DS, Ritter PL, et al. Effect of a self-management program on patients with chronic disease. *Eff Clin Pract* 2001;4:256–62.
19. González VM, Stewart A, Ritter PL, et al. Translation and validation of arthritis outcome measures into Spanish. *Arthritis Rheum* 1995;38:1429–46.
20. Martin RW, Head AJ, Rene J, et al. Patient decision-making related to antirheumatic drugs in rheumatoid arthritis: the importance of patient trust of physician. *J Rheumatol* 2008;35:618–24.
21. Thom DH, Ribisl KM, Stewart AL, et al. Further validation and reliability testing of the Trust in Physician Scale. The Stanford Trust Study Physicians. *Med Care* 1999;37:510–7.
22. Freburger JK, Callahan LF, Currey SS, et al. Use of the Trust in Physician Scale in patients with rheumatic disease: psychometric properties and correlates of trust in the rheumatologist. *Arthritis Rheum* 2003;49:51–8.
23. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. *Med Care* 1986;24:67–74.
24. Gadallah MA, Boulos DN, Gebrel A, et al. Assessment of rheumatoid arthritis patients' adherence to treatment. *Am J Med Sci* 2015;349:151–6.
25. Curtis JR, Yang S, Chen L, et al. Determining the minimally important difference in the Clinical Disease Activity Index for improvement and worsening in early rheumatoid arthritis patients. *Arthritis Care Res (Hoboken)* 2015;67:1345–53.
26. Lee YC, Agnew-Blais J, Malspeis S, et al. Post-traumatic stress disorder and risk for incident rheumatoid arthritis. *Arthritis Care Res (Hoboken)* 2016;68:292–8.
27. Boscarino JA, Forsberg CW, Goldberg J. A twin study of the association between PTSD symptoms and rheumatoid arthritis. *Psychosom Med* 2010;72:481–6.
28. Freedy JR, Steenkamp MM, Magruder KM, et al. Post-traumatic stress disorder screening test performance in civilian primary care. *Fam Pract* 2010;27:615–24.
29. Wilkins KC, Lang AJ, Norman SB. Synthesis of the psychometric properties of the PTSD checklist (PCL) military, civilian, and specific versions. *Depress Anxiety* 2011;28:596–606.
30. Heinze G, Wallisch C, Dunkler D. Variable selection – a review and recommendations for the practicing statistician. *Biom J* 2018;60:431–49.
31. Barton JL, Markwardt S, Schue A, et al. Goal concordance in rheumatoid arthritis: beyond pain reduction, is there agreement [abstract]? *Arthritis Rheum* 2018;70 Supp 1925:2149.
32. Ladin K, Buttafarro K, Hahn E, et al. “End-of-life care? I'm not going to worry about that yet.” Health literacy gaps and end-of-life planning among elderly dialysis patients. *Gerontologist* 2018;58:290–9.
33. Hirsh J, Wood P, Keniston A, et al. Universal health literacy precautions are associated with a significant increase in medication adherence in vulnerable rheumatology patients. *ACR Open Rheumatol* 2020;2:110–8.
34. Li L, Cui Y, Yin R, et al. Medication adherence has an impact on disease activity in rheumatoid arthritis: a systematic review and meta-analysis. *Patient Prefer Adherence* 2017;11:1343–56.
35. Curtis JR, Bykerk VP, Aassi M, et al. Adherence and persistence with methotrexate in rheumatoid arthritis: a systematic review. *J Rheumatol* 2016;43:1997–2009.
36. Voshaar MJ, Vrieseckolk JE, van Dulmen AM, et al. Ranking facilitators and barriers of medication adherence by patients with inflammatory arthritis: a maximum difference scaling exercise. *BMC Musculoskelet Disord* 2021;22:21.
37. McCulley C, Katz P, Trupin L, et al. Association of medication beliefs, self-efficacy, and adherence in a diverse cohort of adults with rheumatoid arthritis. *J Rheumatol* 2018;45:1636–42.